Trial reportEuropean radiology2026
Preoperative MRI assessment of rectal cancer for predicting metastasis-free survival-a post hoc analysis of a randomized controlled clinical trial.
Trial report in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate preoperative MRI risk factors for metastatic disease in patients who underwent neoadjuvant chemoradiotherapy (nCRT) and curative surgery, followed or not by adjuvant chemotherapy (ChT). MATERIALS AND
methodsSingle-center post hoc analysis of a randomized clinical trial data to evaluate the effect of adjuvant ChT in comparison to observation in patients with rectal cancer receiving nCRT and surgical resection. Preoperative MRI variables were retrospectively reviewed by three observers. Clinical, surgical, and pathological variables were included in univariate and multivariate analysis, and metastasis risk was assessed. A subgroup analysis was further performed to evaluate the effect of ChT on metastasis incidence in both good and poor responders to neoadjuvant treatment.
resultsA total of 132 patients (54% female, median age 55 years) were included. Poor mrTRG (HR = 2.53, 95% CI 1.32-5.65) and stage pIII disease (HR 1.94, 95% CI 1.09-3.45) were associated with increased metastatic risk. Although the rate of metastasis was lower in the treated group (9.1%) than in the control group (26.1%) among the patients who achieved a good response (mrTRG 1-2), the difference was not statistically significant (p = 0.19). The subgroup analysis revealed no difference in metastasis rates between patients with poor response receiving or not receiving adjuvant ChT.
conclusionResponse assessed by mrTRG is a preoperative prognostic factor associated with increased metastasis-free survival. MRI restaging could not predict the clinical benefits of adjuvant oxaliplatin-based ChT. KEY POINTS: Question To patients who have rectal cancer, the prediction of risk for metastatic disease during baseline staging to indicate systemic chemotherapy remains challenging. Findings MR-assessed poor tumor regression grade after neoadjuvant chemoradiotherapy (mrTRG3-5) and pathological postoperative nodal positivity are associated with increased metastatic risk. Clinical relevance The unpredictable response to neoadjuvant chemoradiotherapy is a significant driver of prognosis. The metastasis rates among good and poor responders receiving or not receiving adjuvant chemotherapy were similar. Challenges remain in selecting the population that will benefit from additional treatment.
Indexed as
Identifiers
41162756What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.